Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. Earnings Recaps

TNXP Health Care 2 recaps
Next earnings: March 11, 2027 (estimated) · full calendar
Q3 2026 Nov 10, 2026

Tonix shares fell 5.3% after earnings, suggesting investors were not reassured by early launch momentum. While TONMYA sales grew, the launch remains in an early stage, and the transcript points to gross-to-net fluctuations and a newly filed generic challenge as key risks.

Key takeaways
  • TONMYA generated approximately $15 million in third-quarter net sales, up 37% quarter over quarter; management said payer agreements contributed and gross-to-net adjustments were more favorable than expected.
  • Prescriptions rose 28% quarter over quarter to 16,375, including 17% growth in new prescriptions and 56% growth in refills. The expanded 150-rep sales force began field work on September 1, with increases across several prescription and writer metrics since then.
  • Coverage reached approximately 53% of U.S. covered lives. The company also reported improving prescription approval rates among commercially insured patients and fewer bridge prescriptions.
  • Gross-to-net adjustments are expected to fluctuate early in the launch. Separately, Dr. Reddy’s filed an ANDA with a Paragraph IV patent certification for TONMYA; Tonix said it intends to defend its intellectual property.
  • Tonix is advancing Phase II programs in major depressive disorder, Lyme disease prevention, and kidney transplant rejection.
Q2 2026 Aug 13, 2026

Tonix Pharmaceuticals' stock gained modestly by 2.6% post-earnings, reflecting steady early traction in the TONMYA launch but no clear upside surprise. While sales growth was impressive quarter-over-quarter, cautious coverage and access expansion temper enthusiasm and suggest the story remains in early innings.

Key takeaways
  • TONMYA net sales reached approximately $11 million in Q2 2026, nearly tripling the first quarter’s sales, driven by increased prescriptions (+100% QoQ), new patient starts (+36% QoQ), and refills (+207% QoQ).
  • Coverage currently stands at 136 million lives (43% of U.S. covered lives), set to increase to about 145 million (46%) from January 2027 with managed Medicare deal activation.
  • Sales gross-to-net trends remain volatile due to channel mix and prior authorization dynamics; fluctuations expected through year-end.
  • Pipeline progress includes enrollment of the first patient in TNX-102 SL for Major Depressive Disorder and a positive FDA Type C meeting for TNX-4800 Lyme disease prevention, with Phase II enrollment planned for early 2027.
  • Despite encouraging launch metrics, market reaction suggests investors are awaiting broader coverage and sustained sales momentum before committing fully.